EA02

EA02 is a novel tricyclic small molecule derivative of the antipsychotic drug thioridazine, currently under preclinical investigation for the treatment of glioblastoma multiforme (GBM). Developed by researchers at the University of Bergen and University Hospital Cologne, EA02 was designed to retain the chemosensitizing and anti-tumor properties of thioridazine while potentially reducing its associated cardiotoxicity. Preclinical studies have demonstrated that EA02 exhibits selective cytotoxicity against GBM cell lines and glioma stem cells (GSCs) by inducing apoptosis. In animal models, intravenous administration of EA02 has shown limited systemic toxicity at therapeutic concentrations, and ongoing research is evaluating its efficacy in orthotopic xenograft models, both as a monotherapy and in combination with temozolomide (TMZ).